JPRN-UMIN000004978
Completed
Phase 1
Phase I study of weekly intraperitoneal paclitaxel combined with oxaliplatin plus S-1 for advanced gastric cancer with peritoneal metastasis - Phase I study of IP PTX plus SOX
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- gastric cancer with peritoneal metastasis
- Sponsor
- The University of Tokyo Hospital
- Enrollment
- 9
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000023000agoya University50
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin as second-line chemotherapy for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012836The University of Tokyo50
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012834The University of Tokyo50
Completed
Phase 1
Exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intakegastric cancer with peritoneal metastasisJPRN-UMIN000019206The University of Tokyo34
Unknown
Phase 2
Phase II Trial of Weekly Intravenous Paclitaxel plus Three Weekly Intraperitoneal Carboplatin Administration for Suboptimally Debulked Ovarian and Primary Peritoneal Carcinoma Incorporating Pharmacogenomic Analysis.Ovarian Cancer, Peritoneal CancerJPRN-UMIN000001713Development Organization for Frontier Medical Therapeutics80